Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT-PSMA-CART for CRPC
NCT04053062Phase 1Suspended
- Sponsor
- BRL Medicine Inc.
- Start
- Jul 2020
- Primary completion
- May 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LIGHT-PSMA-CART in castration-resistant prostate cancer (CRPC), sponsored by BRL Medicine Inc. Primary endpoint: Incidence of toxicity at 28 days. Started Jul 2020; status: suspended.
02
Drugs
LIGHT-PSMA-CART
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04053062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053062.